A Phase 1 interventional study of acoramidis in Amyloidosis, sponsored by Eidos Therapeutics, a BridgeBio company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Eidos Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Amyloidosis with a site in United Kingdom — 12 open to participants now, 15 under way, 8 of them phase 3. Amyloidosis · United Kingdom.
Among the 49 studies in Amyloidosis with a site in United Kingdom, this one is the 40th largest by enrollment of the 44 interventional ones that give a count, is one of 3 that started in 2021, is one of 13 in phase 1, and was the 32nd registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →12 of the 49 studies in Amyloidosis with a site in United Kingdom are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in United Kingdom, United States, Australia
Ages 18+
Alnylam Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 19 more countries
Ages 18–85
Alexion Pharmaceuticals, Inc. · Sites in United Kingdom, United States, Canada
Ages 18+
Alnylam Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 33 more countries
Ages 18–85
Idoven 1903 S.L. · Sites in United Kingdom, United States, France and 2 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 11 · Phase 3 24
First in 2001; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 143 across the 44 interventional studies, 1,850 across the 5 observational. Of the 33 that completed or were terminated, 17 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 49 have an industry lead sponsor. The 10 most frequent:
This study is registered under Eidos Therapeutics, a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
Eidos Therapeutics, a BridgeBio company is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
BridgeBio has 8 studies filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Amyloidosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06978660Idoven 1903 S.L.Multicenter Study for the Validation of an AI-based ECG Platform for Early Cardiac Amyloidosis Diagnosis | 2026-12 |
| NCT05652335Janssen Research & Development, LLCA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | 2027-04-19 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Amyloidosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.
It is planned to enroll 14 subjects who will receive single oral doses of active IMP in a sequential manner over 5 periods, with a minimum of 7days between dosing in each period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: acoramidis
acoramidis
Also known as: AG10
Pharmacokinetic Assessments: Cmax
Maximum Concentration (Cmax)
Time frame: 72 hours
Pharmacokinetic Assessments: AUC
Area under the plasma concentration-time curve (AUC)
Time frame: 72 hours
Pharmacokinetic Assessments: Tmax
Time to maximum concentration (Tmax)
Time frame: 72 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2021 to primary completion in Aug 2021, 4 months.
Of 18 phase 1 interventional studies under Amyloidosis, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 58. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acoramidis
Eidos Therapeutics, a BridgeBio company →